Citi Maintains Buy on Endo Pharmaceuticals

Citi is out with its report today on Endo Pharmaceuticals ENDP, maintaining Buy. In a note to clients, Citi writes, "We rate the shares of Endo as Buy/High Risk (1H). We expect Lidoderm and the Opana/Opana ER franchise to continue to generate material cash flows for several years beyond their genericization period and believe that the market is discounting the revenue generation potential of especially Lidoderm post genericization too heavily." Shares of ENDP closed Friday at $40.66, up 1.22% from Thursday's close.